Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter study. II. Basophil activation by nonsteroidal anti-inflammatory drugs and its impact on pathogenesis.
BACKGROUND
Patients who are clinically hypersensitive to nonsteroidal anti-inflammatory drugs (NSAIDs) sometimes present basophil activation in vitro, and in 50% of cases a parallel response to release of sulfidoleukotrienes (cellular allergen stimulation test) is observed. These phenomena occur not only in clinically hypersensitive patients, but also in some healthy controls who tolerate NSAIDs.


METHODS
We studied 16 clinically hypersensitive patients, 22 controls tolerating NSAIDs, and 29 healthy blood donors (clinical NSAID status unknown) using 2 different basophil isolation techniques (buffy coat or plasma leukocytes).


RESULTS
In a population of 13 aspirin-tolerant healthy controls and 29 healthy blood donors, basophil activation with aspirin, diclofenac, and naproxen was analyzed at 4 different concentrations. The results in the 2 groups were quite similar in qualitative terms. Choosing a cutoff of 5% and a stimulation index >2, the proportion of positive results increased with the concentration. There were more positive results at all concentrations using the plasma leukocyte technique.


CONCLUSIONS
The most important finding of this study is that basophil activation by NSAIDs occurs not only in clinically hypersensitive patients but also, to a very variable extent and on an individual basis, in apparently normal healthy individuals who tolerate NSAIDs. The phenomenon is clearly dose-related, and hypersensitive patients seem to react to lower NSAID concentrations.
Department of Allergology and Clinical Immunology, University of Navarra, Pamplona, Spain.
A L
AL
De Weck
M L
ML
Sanz
P M
PM
Gamboa
J M
JM
Jermann
M
M
Kowalski
W
W
Medrala
J
J
Sainte-Laudy
M S
MS
Schneider
J M
JM
Weber
A
A
Wolanczyk-Medrala
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001491:Basophils / Q000187:drug effects* / Q000502:physiology; D015936:Complement C5a / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D013577:Syndrome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007073:Immunoglobulin E; D015936:Complement C5a